Analysis of hepatitis B virus genotypes and pre-core region variability during interferon treatment of HBe antigen negative chronic hepatitis B

✍ Scribed by Zhang, Xinxin; Zoulim, Fabien; Habersetzer, François; Xiong, Sidong; Trépo, Christian

• Publisher: John Wiley and Sons
• Year: 1996
• Tongue: English
• Weight: 891 KB
• Volume: 48
• Category: Article
• ISSN: 0146-6615
• DOI: 10.1002/(sici)1096-9071(199601)48:1<8::aid-jmv2>3.0.co;2-e

✦ Synopsis

The clinical importance of hepatitis B virus (HBV) genome variability has been reported recently. One example is the occurrence of hepatitis B virus pre-core mutants, which arise during spontaneous or interferon-induced seroconversion from HBeAg to anti-HBe and are thought to be selected by immune pressure. A survey of HBV pre-core mutants and viral genotypes in 35 HBeAg negative patients during interferon therapy was carried out to understand viral pathogenesis in this form of chronic hepatitis B. Seventeen patients responded to interferon therapy as assessed by the sustained normalization of serum ALT levels and the significant decrease of viremia levels. The response rate to interferon was independent of both initial serum viral DNA level and interferon doses. During interferon therapy, a significant decrease of MO (wild-type pre-core sequence at pos. 1887-19081, M I (TGG to TAG at pos. 1896) or M2 (TGG to TAG at pos. 1896, and GGC to GAC at pos. 1899) positive viral genomes was found in 48%, 42%, and 33% of patients, respectively. A higher response rate to interferon therapy was observed in patients infected with HBV genotype A (70%) or MO positive strains (75%) as compared to patients infected with genotype DIE (40%) or M1IM2 positive strains (44%). The data support the hypothesis that pre-core defective HBV represent viral mutants with an increased capacity to resist exogenous alpha interferon. These findings emphasize that characterization of HBV genome variability prior to interferon therapy may help to predict antiviral response in HBeAg negative patients.